Abstract: A method for controlling the functioning of at least one smart home appliance of a network system comprising a cloud server, a terminal device and at least one smart home appliance registered in said cloud server. The method comprises a phase of creating an activity group comprising: selecting one or more registered smart home appliance; selecting control instructions; associating the selected control instructions to the selected smart home appliances; selecting a trigger event for each one of the selected control instructions; activating said activity group; and the cloud server sending the selected control instructions to the selected smart home appliances according to the trigger event.

Abstract: A system for generating one or more task-specific machine learning models for use in conjunction with one or more accelerated machine learning models is configurable to (i) identify a selected search space from a plurality of pre-defined search spaces; (ii) determine a set of candidate model architectures from the selected search space utilizing model architecture search; (iii) train a set of task-specific machine learning models based upon the set of candidate model architectures using a set of training data comprising input data comprising at least a set of embeddings generated by one or more accelerated machine learning models and task-specific ground truth output; and (iv) output one or more task-specific machine learning models from the set of task-specific machine learning models based upon an evaluation of performance of each task-specific machine learning model.

Abstract: The computer-assisted parallelization of a task capable of being accomplished by a pre-trained machine learning model. Multiple learner models are created by, for each of at least some of the parallel compute resources, selecting one or more characteristics of a learner model based on one or more characteristics of the corresponding compute resource on which the learner model is to run. The learner models are then taught. The teaching occurs such that the learner model is capable of generating a task result when given the task. At task time, the tasks results are then aggregated to generate an aggregated task result. The learner models are thus collectively tailored to run efficiently on the corresponding hardware.

Abstract: A computer-implemented method of determining control signals for controlling an autonomous vehicle to implement a slowdown manoeuvre, comprising: detecting an obstacle at a distance ahead of the autonomous vehicle; comparing the distance with a threshold value and implementing a slowdown manoeuvre in dependence on the comparison, the slowdown manoeuvre selected from: a first slowdown manoeuvre carried out by a kinematic function, which is a time derivative of acceleration, in which a constraint optimisation has been applied to optimise a cost function of the slowdown manoeuvre subject to a set of hard constraints that require a final acceleration, speed and position to satisfy respective acceleration, speed and position targets, given an initial speed and acceleration of the vehicle, and impose a jerk magnitude upper limit; and a second slowdown manoeuvre implemented in an adaptive cruise control mode which aims to reach a target headway between the autonomous vehicle and the obstacle.

Abstract: The present invention concerns a charging cable management system, which is motorized and is applied in electric vehicle charging equipment, or other applications that require this type of solution. The developed charging cable management system allows extending or retracting a suspension cable that assists the user in the task of mobilizing and moving an electric charging cable for charging electric vehicles, preventing it from touching the ground when not in use. In addition, the charging cable management system allows the use and mobilization of charging cables with greater longitudinal amplitude, minimizing the efforts associated with carrying out these tasks by the user.

Abstract: Aspects of the present disclosure provide accelerated transfer learning for machine learning models, such as neural networks, as a service. In doing so, the aspects disclosed herein decouple the conversion process for use of machine learning models from deployment of the models in a production environment through the creation of one or more common generic models that execute on a hardware accelerator, such as a FPGA. Additional aspects of the disclosure relate to the creation of an accelerated machine learning model. The accelerated machine learning model is created by identifying common portions of a machine learning model that can be leveraged by a plurality of different machine learning models. Still further aspects of the disclosure relate to training scenario specific machine learning models for use with an accelerated machine learning model.

Abstract: The invention relates to a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by:

Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.

Abstract: A computer-implemented method of predicting behaviour of an agent for executing an objective of a mobile robot in the vicinity of the agent, in dependence on the predicted behaviour comprises: determining a reference path, wherein multiple actions are available to the agent, and the reference path relates to one of those actions; projecting a measured velocity vector of the agent onto a reference path, thereby determining a projected speed value for the agent along the reference path; computing predicted agent motion data for the agent along the reference path based on the projected speed value; and generating a series of control signals for controlling a mobile robot to fulfil the objective in dependence on the predicted agent motion data.

Abstract: A computer-implemented method of determining a series of control signals for controlling an autonomous vehicle to implement a planned speed change maneuver comprises: receiving from a maneuver planner a position target for the planned speed change maneuver; selecting, from a predetermined family of kinematic functions, a kinematic function for carrying out the planned speed change maneuver, each kinematic function being a first or higher order derivative of acceleration with respect to time; and using the selected kinematic function to determine a series of control signals for implementing the planned speed change maneuver; wherein the kinematic function is selected in a constrained optimization process as substantially optimizing a cost function defined for the speed change maneuver, subject to a set of hard constraints that: (i) require a final acceleration, speed and position corresponding to the selected kinematic function to satisfy, respectively, an acceleration target, a speed target and the position t

Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O— C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.

Abstract: The invention relates to a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by:

Abstract: Devices, methods, computer readable media, and other embodiments are described for automated formal analysis and verification of a circuit design. One embodiment involves accessing a circuit design and a set of default verification targets for the circuit design. A plurality of partitions for the circuit design are then automatically generated, and a first partition is analyzed to generate a first set of verification targets for the first partition based on the set of default verification targets and a set of partition and schedule values for the first partition. A first formal verification analysis is performed on the first partition, the first set of verification targets, and the set of partition and schedule values, and a formal verification output is generated based on the first formal verification analysis. Various embodiments can additionally involve stagnation analysis and additional automation to customize the analysis for each partition.

Abstract: A compound of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein: each R? is QR1; each Q is independently selected from a bond, —C1-C10 alkylene, —C2-C10 alkenylene, —C(O)—, —C(O)O—, —C(O)N(R1)—, —C(O)N(R1)SO2—N(R1)C(O)—, —N(R1)—, —N(SO2(R1)), —N(R1)SO2—C(O)NR4R5—, —N(R4R5)C(O)—, —N(R4R5)—S—, —SO—, —SO2—, —S(O)O—, —SO2N(R1)— and —O—; each R1 is independently selected from H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 haloalkyl, C1-C10 heteroalkyl, aryl, heteroaryl, C3-C10 cycloalkyl, —(C1-C10 alkylene)-C3-C10 cycloalkyl, halogen, cyano, C1-C10 alkylene-aryl, C1-C10 alkylene heteroaryl, C1-C10 heterocycloalkyl and —(C1-C10 alkylene)-C1-C10 heterocycloalkyl. The compounds are inhibitors of HDAC and therefore have potential utility in the therapy of a number of conditions including cancer and inflammation.

Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.

Abstract: The present invention is a compound having the following formula: or a pharmaceutically acceptable salt thereof, wherein e.g. L and Y are each independently an optionally substituted 6-membered nitrogen-containing heteroaryl; M is an optionally substituted 5- to 10-membered heteroaryl; W is a zinc-binding group; each R2 is independently hydrogen or C1-C6 alkyl; and R3 is an aryl or heteroaryl. The compounds are useful as histone deacetylase (HDAC) inhibitors.

Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O— C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.

Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.

Abstract: The invention relates to a compound of formula I: (I) or a pharmaceutically acceptable salt thereof, wherein each R3 is independently selected from H, halo, fluorinated C1-C10 alkyl, —I—C1-C10 alkyl, —NH—C1-C10 alkyl, —S—C1-C10 alkyl, —O-fluorinated C1-C10 alkyl, —NH-acyl, —NH—C(O)—NH-alkyl, —C—(O)—NH-alkyl, with the proviso that at least one of R3 is not H.